Three decades of research, development, and community investment

Graduates from the University of Saskatchewan with a Bachelor of Science in Agricultural Chemistry.

Successfully defends his PhD in Medicine (Psychiatry) at the University of Alberta in November 1993 at age 24. Research focused on the biochemical and neurochemical mechanisms associated with psychiatric and neurodegenerative diseases. The PhD work produced five peer-reviewed research papers.

Develops deep expertise in mass spectrometry technologies and their application to the study of biological systems, the foundational technical knowledge behind all subsequent research.

Invents an advanced mass spectrometry platform capable of non-targeted metabolomics, enabling comprehensive monitoring of human biochemistry at a scale previously not possible. Canadian patent application filed February 2, 2000. Patent →

Invited to Saskatoon to give a seminar at Innovation Place and tour the facility as a potential location for a new company. The facilities, access to university-trained researchers, and the environment at Innovation Place lead to the decision to found the company in Saskatchewan.

Incorporates a Saskatoon-based numbered company (101015930 Saskatchewan Ltd.) on December 19, 2000, as a wholly-owned subsidiary of his holding company, Yolbolsum Canada Inc. (YBCI). The company is renamed Phenomenome Discoveries Inc. (PDI) on March 15, 2001.

Publishes first metabolomics paper. PubMed →

Collaborative metabolomics research published in PNAS. Becomes one of the most cited papers in plant biochemistry.

Discovers novel serum biomarkers of colon cancer and ovarian cancer. Diagnostic test patents filed.

Invents core plasmalogen restoration technology. Lead plasmalogen precursor compound designed and patented. Discovers serum biomarkers of multiple sclerosis and dementia. Diagnostic test patents filed.

Landmark paper establishes the causative role of plasmalogen deficiency in Alzheimer's disease and dementia. PubMed → Autism biomarker discovery and diagnostic test patented.

Saskatchewan colon cancer screening trial begins in partnership with the Saskatchewan Cancer Agency, the Regina Qu'Appelle Health Region, and the Government of Saskatchewan. CBC covers the research positively. Novel pharmaceutical plasmalogen derivatives invented, including PPI-1011. Independent Deloitte and Touche review finds Dr. Goodenowe's compensation as President and CEO is below the 25th percentile of comparable Canadian companies.

Longitudinal autism study published, identifying the role of mitochondrial insufficiency. PubMed →

Colon cancer screening trial completes with nearly 6,000 participants. Biomarker papers published. PubMed → PubMed →

PPI-1011 oral bioavailability published. PubMed → RCDP cell model data published. PubMed →

Saskatchewan colon cancer population study published, demonstrating 86% sensitivity for early-stage detection with a blood assessment. PubMed → Pancreatic cancer biomarker study published with accuracy exceeding 95%. PubMed →

MS biomarker study published. PubMed → Parkinson's primate study published. PubMed → Post-market colon cancer screening analysis of 14,995 patients published. The New York Times profiles RCDP families and the plasmalogen research program. In its August 31, 2015 audited annual report, Golden Opportunities Fund Inc. (GOFI) values PDI at $70.00 per share, representing a total enterprise value of $133,514,150. In late 2015, GOFI demands repayment of an $833,000 loan secured against laboratory equipment.

On February 19, 2016, the PDI board votes in favour of receivership. On February 26, 2016, the company enters court-ordered receivership. Dr. Goodenowe resigns as President and CEO on July 5, 2016. Prodrome Sciences Inc. is incorporated in Saskatchewan on July 6, 2016. On September 16, 2016, the court approves the sale of all PDI assets to Med-Life Discoveries LP for under $5 million. Sales process record → Dr. Goodenowe also incorporates Prodrome Sciences USA LLC in Temecula, California to continue plasmalogen research and product development. Parkinson's mouse model reversal study published. PubMed →

Med-Life Discoveries receives FDA Orphan Drug Designation for PPI-1040, a plasmalogen precursor compound co-invented by Dr. Goodenowe at PDI and acquired by Med-Life through the 2016 receivership. The Med-Life-led RCDP Natural History Trial begins. ClinicalTrials.gov → APOE/plasmalogen study of 1,205 elderly persons published. PubMed → On June 7, 2019, Med-Life Discoveries LP files a Statement of Claim in the Court of Queen's Bench for Saskatchewan, Judicial Centre of Saskatoon, against Yolbolsum Canada Inc., Prodrome Sciences Inc., Prodrome Health Centers Inc., Dr. Goodenowe, and additional defendants. The action remains ongoing.

ADNI consortium Alzheimer's study of 1,547 serum samples published in Alzheimer's and Dementia. PubMed → Bipolar disorder study published. PubMed →

Breast cancer biomarker study with Kyoto University published. PubMed → Breaking Alzheimer's published.

First study of plasmalogen supplementation in cognitively impaired persons published. PubMed → A related paper (PMID 35874835) carries an Expression of Concern posted by Frontiers in January 2026; a research integrity investigation is ongoing. Post-mortem brain analysis published. RCDP charity established to support people living with the disease.

Health Canada issues a No Objection Letter to Med-Life Discoveries for a Phase 1 trial of PPI-1011, the plasmalogen precursor compound co-invented by Dr. Goodenowe at PDI in 2008. This is the first regulatory-approved human trial for a plasmalogen compound. Med-Life Discoveries →

Returns to Moose Jaw. Opens Restorative Health Centre and community facilities. Launches autism, senior engagement, and ALS community programs. Med-Life Discoveries completes Phase 1 dosing of PPI-1011 with no significant safety concerns reported.

In April 2025, Dr. Goodenowe announces a $100 million investment in the Moose Jaw Vitality Project. EINPresswire → Med-Life Discoveries publishes the Phase 1 PPI-1011 safety and pharmacokinetic results in Clinical and Translational Science. Dr. Goodenowe is not a listed author on the paper. PubMed → On June 18, 2025, CBC Saskatchewan publishes the first article in a continuing investigative series. Read the review → On August 8, 2025, Dr. Goodenowe and Lakeview Regional Wellness Centre Inc. file a defamation action against CBC and Geoff Leo in the Court of King's Bench for Saskatchewan, Judicial Centre of Regina. Case KBG-RG-01794-2025 → The Lakeview Wellness Centre is named an ABEX Awards finalist in two categories. On November 30, 2025, CBC publishes an article about the death of Susie Silvestri. From December 1 to 3, 2025, NDP MLA Jared Clarke makes statements in the Legislative Assembly and the Saskatchewan NDP releases a public letter to the Moose Jaw Police Service calling for a criminal investigation. The political response →

On March 4, 2026, OMQ Law writes to Mr. Clarke on behalf of Dr. Goodenowe and Lakeview Regional Wellness Centre Inc., setting out the plaintiffs' position on his statements. A parallel letter is sent to NDP Leader Carla Beck on March 9, 2026. On March 17, 2026, Dr. Goodenowe publishes a video response addressed to residents of Saskatchewan. On March 24, 2026, Lenczner Slaght sends a formal letter to CBC's legal counsel. CBC publishes a tenth article on March 30, 2026. Geoff Sando, a former client and named defendant in a separate California defamation action, passes away on March 27, 2026. On April 9, 2026, a press conference is held at the Lakeview Wellness Centre. In April 2026, the Saskatchewan government tables Bill 55, The Medical Profession Amendment Act, 2026. On April 15, 2026, a Statement of Claim is issued in the Court of King's Bench for Saskatchewan, Judicial Centre of Regina, naming Ms. Beck and Mr. Clarke as defendants. Case KBG-RG-00802-2026. On April 19, 2026, Dr. Goodenowe writes to the Saskatchewan Ministers of Health, Justice, and Mental Health and Addictions, opposing Bill 55 in its present form and proposing amendments. On April 28, 2026, CBC reports that the College of Physicians and Surgeons of Saskatchewan welcomes the powers Bill 55 would grant; Dr. Goodenowe responds on the record opposing the bill. Bill 55 is referred to the Standing Committee on Human Services on April 28, 2026. On May 4, 2026, the committee considers the bill; NDP MLA Meara Conway names Dr. Goodenowe and the Lakeview Regional Wellness Centre operation multiple times, and Minister of Health Jeremy Cockrill confirms that the Moose Jaw situation identified the gap the bill addresses. On May 5, 2026, OMQ Law writes to Ministers Cockrill and McLeod, formally objecting to the committee process and proposing eight specific amendments. Later that same day, the bill is read a third time and passed on a voice vote, without amendment and without debate. Bill 55 awaits royal assent.